- Charles River Launches Viral Vector Tech Transfer Program to Safeguard Gene Therapy Development
- Charles River Laboratories Announces First-Quarter 2024 Results
- Charles River Launches Viral Vector Reference Materials to Streamline the Transition to GMP
- Charles River Laboratories Achieves 100% Renewable Electricity Usage Globally
- Charles River Laboratories Launches Alternative Methods Advancement Project to Reduce Reliance on Animal Testing
- Charles River Laboratories Schedules First-Quarter 2024 Earnings Release and Conference Call
- Charles River and Deciphex Launch Patholytix Foresight, a Transformative AI-Powered Decision Support Tool for Toxicologic Pathology
- Charles River Announces Rare Disease Gene Therapy Collaboration with Axovia Therapeutics
- Charles River to Perform Plasmid Production for Ship of Theseus
- Charles River Laboratories Showcases Technology-Driven Capabilities at AACR 2024
More ▼
Key statistics
On Friday, Charles River Laboratories International Inc (CRL:NYQ) closed at 208.44, 28.95% above the 52 week low of 161.65 set on Nov 01, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 209.90 |
---|---|
High | 211.69 |
Low | 206.39 |
Bid | 195.00 |
Offer | 249.23 |
Previous close | 208.44 |
Average volume | 491.83k |
---|---|
Shares outstanding | 51.51m |
Free float | 51.00m |
P/E (TTM) | 24.46 |
Market cap | 10.74bn USD |
EPS (TTM) | 8.52 USD |
Data delayed at least 15 minutes, as of May 31 2024 21:10 BST.
More ▼